Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery

Next Previous
X
Search
Trial Profile

Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 15 Oct 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary) ; Tranexamic acid (Primary)
  • Indications Subdural haematoma
  • Focus Therapeutic Use

    • Most Recent Events

    • 05 Oct 2021 Status changed from recruiting to discontinued.
    • 23 May 2020 Planned End Date changed from 30 Nov 2020 to 31 Dec 2022.
    • 23 May 2020 Planned primary completion date changed from 31 May 2020 to 30 Jun 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top